High-dose cytosine arabinoside for acute nonlymphocytic leukemia
- 31 December 1983
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 16 (1) , 59-66
- https://doi.org/10.1002/ajh.2830160108
Abstract
Eighteen patients with acute nonlymphocytic leukemia (ANLL), aged 17–73 years, were treated with high‐dose cytosine arabinoside (HD‐Ara‐C)) using 3 g/m2 IV q 12 hours × 12 doses. Seven patients were treated for relapse and four (57%) obtained a complete remission with a median duration of 19.5 weeks. In nine patients, refractory to conventional chemotherapy, no complete responders were observed. Treatment failure was most commonly due to drug resistance. Two elderly patients with ANLL not previously exposed to chemotherapy died during the initial induction. Recent data on the HD‐Ara‐C experience in ANLL are presented and compared with this study.Keywords
This publication has 14 references indexed in Scilit:
- Therapy of Secondary Acute Nonlymphocytic Leukemia with CytarabineNew England Journal of Medicine, 1983
- High Dose Cytosine Arabinoside in the Management of Refractory Acute LeukaemiaScandinavian Journal of Haematology, 1982
- Central nervous system toxicity of high-dose systemic cytosine arabinosideCancer, 1981
- Corneal Toxicity with Systemic CytarabineAmerican Journal of Ophthalmology, 1981
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979
- Failure of remission induction in acute myelocytic leukemiaMedical and Pediatric Oncology, 1978
- Treatment of acute myeloid leukaemia with a triple cytotoxic regime: datBritish Journal of Cancer, 1977
- HIGH REMISSION-INDUCTION RATE IN ACUTE MYELOID LEUKÆMIAThe Lancet, 1977
- Cytidine Deaminase and the Development of Resistance to Arabinosyl CytosineNature New Biology, 1971
- Studies on drug resistance—II. Kinase patterns in P815 neoplasms sensitive and resistant to 1-β-d-arabinofuranosylcytosineBiochemical Pharmacology, 1970